Form 4 for XAIR Beyond Air, Inc.
Accepted 2024-10-01 00:00:00 ET · period of report 2024-09-26 · accession 0001493152-24-039088 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2024-10-01 | 2024-09-26 | XAIR | Carey Robert | Dir | P - Purchase | $0.5 | +1.48M | 1.48M | New | +$738.3K |
| DMI | 2024-10-01 | 2024-09-26 | XAIR | Carey Robert | Dir | P - Purchase | — | +2.49M | 26.1K | New | — |
| DI | 2024-10-01 | 2024-09-27 | XAIR | Carey Robert | Dir | J - Other | — | +9.89M | 9.89M | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-09-26 | P | A | 1,476,626 | $0.5 | 1,476,626 | I The Carey 2020 Acelyrin Trust DTD 07/23/2020 | — | — | |
| 2 | Derivative | Pre-funded Warrants to purchase Common Stock | 2024-09-26 | P | A | 480,179 | — | 480,179 | I By: Robert F. Carey III Trust DTD 4/25/01 | $0.00 · — to — | 480,179 Common Stock | (F3) Each pre-funded warrant was purchased with an accompanying warrant for a purchase price of $0.5042 per pre-funded warrant and accompanying warrant. (F2) The pre-funded warrants will be exercisable on or after the date on which the Company obtains stockholder approval (the "Initial Exercise Date"), as further described in the Agreement and in the Issuer's Current Report on Form 8-K filed with the SEC on September 27, 2024, and shall expire when exercised in full. |
| 3 | Derivative | Warrants to purchase Common Stock | 2024-09-26 | P | A | 102,382 | — | 102,382 | I By: The Carey 2020 Acelyrin Trust DTD 07/23/2020 | $0.38 · — to — | 102,382 Common Stock | (F5) Each common share was purchased with an accompanying warrant for a purchase price of $0.5043 per share and accompanying warrant. (F4) The common warrants are exercisable on or after the Initial Exercise Date and will have a term that expires five years following the Initial Exercise Date. |
| 4 | Derivative | Warrants to purchase Common Stock | 2024-09-26 | P | A | 1,880,565 | — | 1,880,565 | I By: Robert F. Carey III Trust DTD 4/25/01 | $0.38 · — to — | 1,880,565 Common Stock | (F5) Each common share was purchased with an accompanying warrant for a purchase price of $0.5043 per share and accompanying warrant. (F4) The common warrants are exercisable on or after the Initial Exercise Date and will have a term that expires five years following the Initial Exercise Date. |
| 5 | Derivative | Warrants to purchase Common Stock | 2024-09-27 | J | A | 9,886,633 | — | 9,886,633 | I By: BCR8V, LLC | $0.38 · — to — | 9,886,633 Common Stock | (F6) Pursuant to a binding term sheet dated as of September 27, 2024, and in connection with a loan to the Issuer of $7,500,000, the Reporting Person acquired warrants to purchase up to 9,886,633 shares of Common Stock. (F7) The warrants issuable will be exercisable on or after the Initial Exercise Date and will expire five years following such date they are exercisable. |
| 6 | Derivative | Pre-funded Warrants to purchase Common Stock | 2024-09-26 | P | A | 26,142 | — | 26,142 | I By: The Carey 2020 Acelyrin Trust DTD 07/23/2020 | $0.00 · — to — | 26,142 Common Stock | (F3) Each pre-funded warrant was purchased with an accompanying warrant for a purchase price of $0.5042 per pre-funded warrant and accompanying warrant. (F2) The pre-funded warrants will be exercisable on or after the date on which the Company obtains stockholder approval (the "Initial Exercise Date"), as further described in the Agreement and in the Issuer's Current Report on Form 8-K filed with the SEC on September 27, 2024, and shall expire when exercised in full. |